Early modulation of gene expression used as a biomarker for chemoprevention in a preclinical model of colon carcinogenesis

Pathology International

Volumn 61, Issue 2, 2011, Pages 80-87

  Bousserouel, Souad ^a,b   Lamy, Virginie ^a,b   Gossé, Francine ^a,b   Lobstein, Annelise ^c   Marescaux, Jacques ^b   Raul, Francis ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b IRCAD   (France)

^c CNRS   (France)

Author keywords

Aberrant crypt foci; Apoptosis; Chemoprevention; Colon carcinogenesis; Inflammation; Innate immunity; Matrix metalloproteinase

Indexed keywords

ALPHA DEFENSIN; ALPHA DEFENSIN 5; AZOXYMETHANE; INTERLEUKIN 1BETA; LUPULON; MATRILYSIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN BAX; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; INFLAMMATION; INTESTINAL MUCOSA; MALE; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TERPENES; TUMOR MARKERS, BIOLOGICAL;

EID: 78751687834     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2010.02621.x     Document Type: Article

References (41)

1. Reddy BS. Studies with azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen 2004; 44: 26-35.
2. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon cancer chemoprevention in rats, mice and humans. Eur J Cancer 2005; 41: 1911-22.
3. Lamy V, Roussi S, Chaabi M etal. Chemopreventive effects of lupulone, a hop β-acid, on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis. Carcinogenesis 2007; 28: 1575-81.
4. Bousserouel S, Gossé F, Bouhadjar M, Soler L, Marescaux J, Raul F. Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis. Oncol Rep 2010; 23: 511-17.
5. Terpstra OT, Van Blankenstein M, Dees J, Eilers GA. Abnormal pattern of cell proliferation in the entire colonic mucosa of patients with colon adenoma or cancer. Gastroenterology 1987; 92: 704-8.
6. Ponz de Leon M, Roncucci L, Di Donato P etal. Pattern of epithelial cell proliferation in colorectal mucosa of normal subjects and of patients with adenomatous polyps or cancer of the large bowel. Cancer Res 1988; 48: 4121-6.
7. Risio M, Lipkin M, Candelaresi G, Bertone A, Coverlizza S, Rossini FP. Correlations between rectal mucosa cell proliferation and the clinical and pathological features of nonfamilial neoplasia of the large intestine. Cancer Res 1999; 151: 1917-21.
8. Takayama T, Katsuki S, Takahashi Y etal. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339: 1277-84.
9. Bird RP, Good K. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 2000; 112-113: 395-402.
10. Pereira MA, Barnes LH, Rassman VL, Kelloff GV, Steele VE. Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 1994; 15: 1049-54.
11. Bousserouel S, Kauntz H, Gossé F, Soler L, Marescaux J, Raul F. Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. Int J Oncol 2010; 36: 1485-90.
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8.
13. Somiari SB, Shriver CD, Heckman C etal. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett 2006; 233: 98-107.
14. Sier CF, Hawinkels LJ, Zijlmans HJ etal. Endothelium specific matrilysin (MMP-7) expression in human cancers. Matrix Biol 2008; 27: 267-71.
15. Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 2006; 20: 983-1002.
16. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev 2007; 87: 1285-342.
17. Gunter MJ. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 1126-31.
18. Buck I, Morceau F, Grigorakaki C, Dicato M, Diederich M. Linking anemia to inflammation and cancer: The crucial role of TNFα. Biochem Pharmacol 2009; 77: 1572-9.
19. Ramasundara M, Leach ST, Lemberg DA, Day AS. Defensins and inflammation: The role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol 2009; 24: 202-8.
20. Lamy V, Roussi S, Chaabi M, Gossé F, Lobstein A, Raul F. Lupulone, a hop bitter acid, activates different death pathways involving apoptotic TRAIL-receptors, in human colon tumor cells and in their derived metastatic cells. Apoptosis 2008; 13: 1232-42.
21. Ali MA, Sjöblom T. Molecular pathways in tumor progression: From discovery to functional understanding. Mol Biosyst 2009; 5: 902-8.
22. McLellan EA, Medline A, Bird RP. Dose-response and proliferative characteristics of aberrant crypt foci: Putative preneoplastic lesions in rat colon. Carcinogenesis 1991; 12: 2093-8.
23. Magnuson BA, Carr I, Bird RP. Ability of aberrant crypt foci characteristics to predict colonic tumor incidence in rats fed cholic acid. Cancer Res 1993; 53: 4499-504.
24. Cheng L, Lai MD. Aberrant crypt foci as microscopic precursors of colorectal cancer. World J Gastroenterol 2003; 9: 2642-9.
25. Leeman MF, Curran S, Murray GI. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 2003; 201: 528-34.
26. Lu Q, Jiang B, Lin C, Shan T. Dark aberrant crypt foci with activated Wnt pathway are related to tumorigenesis in the colon of AOM-treated rat. J Exp Clin Cancer Res 2008; 27: 26.
27. Friedl P, Wolf K. Tumor-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-74.
28. Tu S, Bhagat G, Cui G etal. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 14: 408-19.
29. Deichman GI. Natural selection and early changes of phenotype of tumor cells in vivo: Acquisition of new defense mechanisms. Biochemistry 2000; 65: 78-94.
30. Cunliffe RN. Defensins in the gastrointestinal tract. Mol Immunol 2003; 40: 463-7.
31. Papo NSY. Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 2005; 62: 784-90.
32. Friedl A, Stoesz SP, Buckley P, Gould MN. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J 1999; 31: 433-41.
33. Jayaraman A, Roberts KA, Yoon J etal. Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1beta: A proteomic analysis. Biotechnol Bioeng 2005; 91: 502-15.
34. Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL. Reduced α-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut 2008; 57: 903-10.
35. Zhang J, Wu Y, Zhang Y, Leroith D, Bernlohr DA, Chen X. The Role of Lipocalin 2 in the Regulation of Inflammation in Adipocytes and Macrophages. Mol Endocrinol 2008; 22: 1416-26.
36. Jishu S. A novel role for defensins in intestinal homeostasis: Regulation of IL-1 secretion. J Immunol 2007; 179: 1245-53.
37. Lee HJ, Lee EK, Lee KJ, Hong SW, Yoon Y, Kim JS. Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer 2006; 118: 2490-97.
38. Huang HL, Chu ST, Chen YH. Ovarian steroids regulate 24p3 expression in mouse uterus during the natural estrous cycle and the preimplantation period. J Endocrinol 1999; 162: 11-19.
39. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL), Modulation of MMP-9 activity by NGAL. J Biol Chem 2001; 276: 37258-65.
40. Leng X, Lin H, Ding T etal. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene 2008; 27: 6110-19.
41. Eastwood GL. A review of gastrointestinal epithelial renewal and its relevance to the development of adenocarcinomas of the gastrointestinal tract. J Clin Gastroenterol 1995; 21: S1-11.